SCHEMBL6477879

SCHEMBL6477879

CC1=C2N=C(C(=O)O)ON2C(=O)C(Cc2ccc(F)c(F)c2)C1=O

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
KDM5B Q9UGL1 1/20 0.33
P2RY14 Q15391 1/20 0.32
ALDH1A1 P00352 3/20 0.31
ANO1 Q5XXA6 1/20 0.31
MAOA P21397 1/20 0.31
MAOB P27338 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.31
CNR1 P21554 3/20 0.30
TSHR P16473 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
CNR2 P34972 1/20 0.30
LMNA P02545 1/20 0.30
P2RX7 Q99572 1/20 0.30
PTGER1 P34995 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6814261 0.91 MEN1 (0.33) KDM5AKDM4CKDM5BALDH1A1
SCHEMBL6814255 0.90 KDM5A (0.33) KDM5AKDM4CKDM5BALDH1A1
SCHEMBL6814257 0.83 NAMPT (0.39) ALDH1A1L3MBTL1LMNA
SCHEMBL6477074 0.77 CES2 (0.33) KDM5AKDM4CKDM5BP2RY14ALDH1A1
SCHEMBL6486635 0.77 P2RY14 (0.32) P2RY14ALDH1A1PTGDR2CNR1TSHR
SCHEMBL6484477 0.72 HCAR3 (0.32) P2RY14ALDH1A1ANO1CNR1TSHR
SCHEMBL6477346 0.71 CES2 (0.36) P2RY14ALDH1A1P2RX7
SCHEMBL6482492 0.71 DAO (0.34) KDM5AKDM5BP2RY14ALDH1A1TSHR
SCHEMBL6488442 0.70 ALDH1A1 (0.34) P2RY14ALDH1A1CNR1TSHRL3MBTL1
SCHEMBL6484455 0.67 PTGER4 (0.38) ALDH1A1TSHRP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6897223-B2 Pyridine fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-05-24 US disclosed
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US disclosed
WO-2004014908-A1 HETEROBICYLCIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 KDM5A 555/4885KDM4C 746/4885KDM5B 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.